Of the drugs associated with CDKN2B-AS1, Lapatinib, a dual inhibitor of EGFR and HER2, is indicated for patients with advanced or metastatic BC treatment whose tumors overexpress HER2. This evidence concerns the gene CDKN2B and breast cancer.